image by: HWN

HWN Suggests

Midi’s Definitive Guide to Menopause Treatment for Breast Cancer Survivors & Women At Risk

Navigating menopause after breast cancer treatment can bring a unique set of challenges, and many women wonder if hormone replacement therapy (HRT) is a viable option. The good news: No matter your cancer status, there are safe, effective treatment options to help manage hot flashes, brain fog, vaginal dryness, and everything in between. Whether you're a survivor, at high risk, or undergoing cancer therapies that impact estrogen, understanding the latest science and resources can help you make informed decisions about your care. Here's the good news: Whether you’re a breast cancer survivor, carry a gene that increases your risk of developing breast cancer, or you’re considered high-risk because…

read full article

Featured

 Experts call for change of heart on hormone replacement therapy after breast cancer

For women with low-risk breast cancer, HRT increases the risk of relapse from 5% to 7.2%. This means that despite use of HRT, 92.8% of women with low-risk disease will not experience a relapse. “As a panel of experts, the consensus was that we should move away from a de facto ban of HRT after breast cancer diagnosis towards a more nuanced, evidence-based discussion that respects each woman’s circumstances, values and preferences.”

 Hormonal Replacement Therapy in Cancer Survivors: Safety, Benefits, and Clinical Guidelines

Some guidelines cautiously permit local estrogen in highly symptomatic patients after other treatments—such as vaginal moisturizers, lubricants, or non-hormonal pharmacotherapy—have failed, but decisions should be individualized and made in collaboration with the oncology team.

 Vaginal estrogen use in breast cancer survivors: a systematic review and meta-analysis of recurrence and mortality risks

The use of vaginal estrogen in patients with a history of breast cancer does not appear to be associated with an increased risk of breast cancer recurrence, breast cancer-specific mortality, or overall mortality.

Articles of Interest

A guide to menopause if you’ve had breast cancer

Vaginal hormones, also known as local hormones, are different to HRT as they are very low dose and do not get absorbed into your body. They can usually safely be prescribed for women who have had any type of breast cancer.

Benefits and risks of HRT before and after a Breast Cancer Diagnosis

This is an important and controversial topic. The risk of breast cancer diagnosis associated with hormone replacement therapy (HRT) is often assumed by health care professionals and the lay public alike to be very high, which may adversely influence decisions about its initiation and continuance. This is despite the fact that most women will not be diagnosed in their lifetime and any risk conferred by HRT is comparable or less than that of other postmenopausal lifestyle risk factors for breast cancer (e.g. obesity, alcohol).

Bioidentical Hormones for Breast Cancer Survivors by Jeffrey Dach MD

Several case-control and cohort studies have noted either no increased risk or actually less risk of recurrence in women taking estrogen after therapy after breast cancer. Although the general consensus is that such a recommendation is contraindicated, the data do not support this admonition.

Climacteric Complaints after Breast Cancer – Is HRT an Option?

Despite these caveats, the severity of symptoms and the lack of effective alternatives still cause many women to opt for HRT. Nevertheless, HRT cannot generally be recommended as first-line therapy for climacteric complaints in women with a history of breast cancer. It may, however, be a valid option for selected women with climacteric symptoms refractory to previous non-hormonal treatments. In these cases, an individualized risk-benefit analysis is imperative before treatment initiation, and a treatment duration of less than 5 years with intermittent withdrawal attempts should be aimed for.

Experts reach consensus on HRT after breast cancer

These investigators reached consensus about key HRT-related statements, including vaginal oestrogen being unlikely to increase the risk of breast cancer recurrence and systemic HRT increasing relapse risk in women with oestrogen receptor (ER) positive breast cancer. Investigators recommended patients taking HRT after breast cancer be enrolled in clinical trials.

Hormone Replacement for Breast Cancer Survivors Part Two

The mainstream medical dogma is that hormone replacement is contraindicated for the breast cancer survivor (BCS) for fear of inducing recurrent cancer or a new cancer. In part one of this series, the opposite argument was presented. We now have 25 studies showing hormone replacement is beneficial for the BCS’s quality of life, without increased breast cancer recurrence compared to controls. Perhaps the strongest advocate for treating the BCS with BHRT is Avrum Bluming, MD, now retired after 50 years practicing oncology in Encino, California.

Hormone Replacement for Breast Cancer Survivors Part Two

The mainstream medical dogma is that hormone replacement is contraindicated for the breast cancer survivor (BCS) for fear of inducing recurrent cancer or a new cancer. In part one of this series, the opposite argument was presented. We now have 25 studies showing hormone replacement is beneficial for the BCS’s quality of life, without increased breast cancer recurrence compared to controls. Perhaps the strongest advocate for treating the BCS with BHRT is Avrum Bluming, MD, now retired after 50 years practicing oncology in Encino, California.

Hormone Replacement Therapy (HRT) and Breast Cancer Risk: What the Latest Research Reveals

A limited number of studies have shown that cognitive behavioral therapy, acupuncture, and yoga may help improve a subset of the symptoms associated with menopause. In addition, topical HRT and vaginal moisturizers may be an option for women with a history of breast cancer who are experiencing some vaginal symptoms associated with menopause. In fact, a recent retrospective study found that vaginal estrogen use in patients with a history of breast cancer actually increased breast cancer–specific and overall survival compared to patients who did not use vaginal estrogen.

Hormone Replacement Therapy After Breast Cancer: It Is Time

Even in the HABITS trial, the absolute increase in the number of women who had a recurrence (localized only) associated with HRT administration was 22. It is on the basis of these 22 patients that HRT, with its demonstrated benefits for so many aspects of women's health, is being denied to millions of breast cancer survivors around the world.

Hormone replacement therapy in female-specific cancer survivors: considerations beyond cancer cure

This review provides an updated overview of HRT in women with a history of cervical, endometrial, ovarian, and breast cancers. For cervical cancer, HRT is not contraindicated in either squamous cell carcinoma or adenocarcinoma, regardless of stage. For endometrial cancer, HRT is not contraindicated in early-stage disease with no residual tumor, although it should be avoided in low-grade endometrial stromal sarcoma. HRT is not contraindicated in epithelial ovarian cancer regardless of stage, except in low-grade serous carcinoma. Currently, HRT is contraindicated for breast cancer.

Menopausal Hormone Therapy in Breast Cancer Survivors

There is a paucity of data relating to the impact of MHT on oncological outcomes in breast cancer patients. Interpretation of clinical trials and observational studies is hampered by heterogenicity, small numbers, a short follow up and retrospective nature. Defining a risk of recurrence for breast cancer survivors using MHT is imperative and oncological risk must be weighed against quality of life, as well as long-term benefits of estrogen for osteoporosis and cardiovascular disease.

Safety of using hormone replacement therapy in breast cancer survivors: A systematic review and metanalysis

Use of HRT significantly increases the risk of recurrence in BC survivors, particularly in those with hormone receptor-positive disease. Therefore, this approach remains contraindicated in this setting. Alternative interventions to mitigate menopause-related symptoms should be proposed to these patients.

Why Doctors Are Rethinking HRT for Breast Cancer Survivors

For decades, breast cancer survivors going through menopause have been told that hormone therapy is off-limits—full stop. But new analyses and a 2025 expert consensus paper suggest that there may be safe options for some women. “The data continually points to hormones being safe after breast cancer,” says Jenn Simmons, M.D., an integrative oncologist and breast surgeon in Philadelphia. “And the thing that we are repeatedly missing is why the opposite message was ever put out there, why it has remained out there, and why it is so pervasive.”

Resources

Midi

Get the midlife care you deserve, the prescriptions you need, and the insurance coverage you've worked hard for.